Long-term anticoagulant therapy for idiopathic pulmonary embolism in the elderly: A decision analysis

Chest

Volumn 135, Issue 5, 2009, Pages 1243-1251

  Haspel, Jeffrey ^a   Bauer, Kenneth ^a   Goehler, Alexander ^b   Roberts, David H ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Anticoagulation; Decision analysis; Elderly; Pulmonary embolism; Warfarin

Indexed keywords

WARFARIN;

ADULT; AGE DISTRIBUTION; AGED; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; DEEP VEIN THROMBOSIS; DRUG EFFECT; EVENT FREE SURVIVAL; FALLING; FEMALE; HUMAN; IDIOPATHIC DISEASE; LIFE EXPECTANCY; LONG TERM CARE; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; PRIORITY JOURNAL; PROBABILITY; RECURRENT DISEASE; RISK FACTOR; SENSITIVITY ANALYSIS; THROMBOEMBOLISM; TREATMENT DURATION;

EID: 65949101220     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.08-1164     Document Type: Article

References (42)

1. Spyropoulos AC, Merli G. Management of venous thromboembolism in the elderly. Drugs Aging 2006; 23:651-671 (Pubitemid 44394947)
2. Kniffin WD Jr, Baron JA, Barrett J, et al. The epidemiology of diagnosed pulmonary embolism and deep venous thrombosis in the elderly. Arch Intern Med 1994; 154:861-866
3. Cushman M, Tsai AW, White RH, et al. Deep vein thrombosis and pulmonary embolism in two cohorts: the longitudinal investigation of thromboembolism etiology. Am J Med 2004; 117:19-25
4. Eight-year follow-up of patients with permanent vena cava filters in the prevention of pulmonary embolism: the PREPIC (Prevention du Risque d'Embolie Pulmonaire par Interruption Cave) randomized study. Circulation 2005; 112:416-422 (Pubitemid 41022084)
5. Douketis JD, Kearon C, Bates S, et al. Risk of fatal pulmonary embolism in patients with treated venous thromboembolism. JAMA 1998; 279:458-462
6. Buller HR, Agnelli G, Hull RD, et al. Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126(suppl):401S-428S
7. Agnelli G, Prandoni P, Becattini C, et al. Extended oral anticoagulant therapy after a first episode of pulmonary embolism. Ann Intern Med 2003; 139:19-25
8. Agnelli G, Prandoni P, Santamaria MG, et al. Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis: warfarin Optimal Duration Italian Trial Investigators. N Engl J Med 2001; 345:165-169 (Pubitemid 32662124)
9. van Dongen CJ, Vink R, Hutten BA, et al. The incidence of recurrent venous thromboembolism after treatment with vitamin K antagonists in relation to time since first event: a meta-analysis. Arch Intern Med 2003; 163:1285-1293 (Pubitemid 36676193)
10. Goldhaber SZ. Low intensity warfarin anticoagulation is safe and effective as a long-term venous thromboembolism prevention strategy. J Thromb Thrombolysis 2006; 21:51-52 (Pubitemid 43231128)
11. Ridker PM, Goldhaber SZ, Danielson E, et al. Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. N Engl J Med 2003; 348:1425-1434
12. Kearon C, Kahn SR, Agnelli G, et al. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 2008; 133(suppl):454S-545S
13. Gattellari M, Worthington J, Zwar N, et al. Barriers to the use of anticoagulation for nonvalvular atrial fibrillation: a representative survey of Australian family physicians. Stroke 2008; 39:227-230
14. Hylek EM, Evans-Molina C, Shea C, et al. Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation 2007; 115:2689-2696
15. Fang MC, Go AS, Hylek EM, et al. Age and the risk of warfarin-associated hemorrhage: the anticoagulation and risk factors in atrial fibrillation study. J Am Geriatr Soc 2006; 54:1231-1236
16. McMahan DA, Smith DM, Carey MA, et al. Risk of major hemorrhage for outpatients treated with warfarin. J Gen Intern Med 1998; 13:311-316
17. Gage BF, Birman-Deych E, Kerzner R, et al. Incidence of intracranial hemorrhage in patients with atrial fibrillation who are prone to fall. Am J Med 2005; 118:612-617
18. Kyrle PA, Minar E, Bialonczyk C, et al. The risk of recurrent venous thromboembolism in men and women. N Engl J Med 2004; 350:2558-2563
19. Kreke JE, Schaefer AJ, Roberts MS. Simulation and critical care modeling. Curr Opin Crit Care 2004; 10:395-398
20. Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Making 1993; 13:322-338 (Pubitemid 24013155)
21. Arias E. United States life tables, 2002. Natl Vital Stat Rep 2004; 53:1-38
22. Satish S, Freeman DH Jr, Ray L, et al. The relationship between blood pressure and mortality in the oldest old. J Am Geriatr Soc 2001; 49:367-374
23. Wells PS, Forgie MA, Simms M, et al. The outpatient bleeding risk index: validation of a tool for predicting bleeding rates in patients treated for deep venous thrombosis and pulmonary embolism. Arch Intern Med 2003; 163:917-920
24. Stain M, Schonauer V, Minar E, et al. The post-thrombotic syndrome: risk factors and impact on the course of thrombotic disease. J Thromb Haemost 2005; 3:2671-2676
25. Briggs AH, Goeree R, Blackhouse G, et al. Probabilistic analysis of cost-effectiveness models: choosing between treatment strategies for gastroesophageal reflux disease. Med Decis Making 2002; 22:290-308
26. Aujesky D, Smith KJ, Roberts MS. Oral anticoagulation strategies after a first idiopathic venous thromboembolic event. Am J Med 2005; 118:625-635 (Pubitemid 40732702)
27. Campbell IA, Bentley DP, Prescott RJ, et al. Anticoagulation for three versus six months in patients with deep vein thrombosis or pulmonary embolism, or both: randomised trial. BMJ 2007; 334:674
28. Eichinger S, Weltermann A, Minar E, et al. Symptomatic pulmonary embolism and the risk of recurrent venous thromboembolism. Arch Intern Med 2004; 164:92-96
29. Prandoni P, Noventa F, Ghirarduzzi A, et al. The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism: a prospective cohort study in 1,626 patients. Haematologica 2007; 92:199-205
30. Buller HR, Cohen AT, Davidson B, et al. Extended prophylaxis of venous thromboembolism with idraparinux. N Engl J Med 2007; 357:1105-1112
31. Sarasin FP, Bounameaux H. Duration of oral anticoagulant therapy after proximal deep vein thrombosis: a decision analysis. Thromb Haemost 1994; 71:286-291 (Pubitemid 24083737)
32. Fang MC, Go AS, Chang Y, et al. Death and disability from warfarin-associated intracranial and extracranial hemorrhages. Am J Med 2007; 120:700-705
33. Palareti G, Leali N, Coccheri S, et al. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT); Italian Study on Complications of Oral Anticoagulant Therapy. Lancet 1996; 348:423-428 (Pubitemid 26267872)
34. Shireman TI, Mahnken JD, Howard PA, et al. Development of a contemporary bleeding risk model for elderly warfarin recipients. Chest 2006; 130:1390-1396
35. Go AS, Hylek EM, Chang Y, et al. Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice? JAMA 2003; 290:2685-2692
36. Kahn SR, Kearon C, Julian JA, et al. Predictors of the post-thrombotic syndrome during long-term treatment of proximal deep vein thrombosis. J Thromb Haemost 2005; 3:718-723
37. Prandoni P, Lensing AW, Cogo A, et al. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med 1996; 125:1-7
38. Nelson MR, Liew D, Bertram M, et al. Epidemiological modelling of routine use of low dose aspirin for the primary prevention of coronary heart disease and stroke in those aged ≥ 70. BMJ 2005; 330:1306
39. Heit JA. The epidemiology of venous thromboembolism in the community: implications for prevention and management. J Thromb Thrombolysis 2006; 21:23-29 (Pubitemid 43231124)
40. Copland M, Walker ID, Tait RC. Oral anticoagulation and hemorrhagic complications in an elderly population with atrial fibrillation. Arch Intern Med 2001; 161:2125-2128 (Pubitemid 36231508)
41. Frazee LA, Chomo DL. Duration of anticoagulant therapy after initial idiopathic venous thromboembolism. Ann Pharmacother 2003; 37:1489-1496 (Pubitemid 37205508)
42. Tran HA. Low-intensity versus conventional-intensity warfarin for prevention of recurrent venous thromboembolism. N Engl J Med 2003; 349:2164-2167